VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

T. pallidum TmpB Protein Vaccine
Vaccine Information
  • Vaccine Ontology ID: VO_0004025
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant TmpB protein.
  • TmpB gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: Ribi vaccine adjuvant
  • Immunization Route: Subcutanteous and i.p.
Host Response

Guinea pig Response

  • Host Strain: C4D
  • Vaccination Protocol: In the first set of experiments, guinea pigs assigned randomly to seven groups of five animals each were immunized with TmpA, TmpB, TmpC, TmpA plus TmpB plus TmpC (TmpABC), or E. coli membranes. Five animals received adjuvant in phosphate-buffered saline, and five guinea pigs served as nonimmunized control. Each animal received six injections, each of 100 μg of antigen in a 0.4-ml volume, distributed in two subcutaneous injections (0.15 ml each) in the inguinal lymph nodes areas and one intraperitoneal injection (0.1 ml) (Wicher et al., 1991).
  • Challenge Protocol: A week after immunizing injection 6, all animals, including untreated controls, were injected intradermally in a hind leg with 100 μl of suspension containing 3 X 106 T. pallidum Nichols freshly extracted from rabbit testes.
  • Efficacy: Guinea pigs receiving TmpB antigen demonstrated protection expressed by the development of significantly (P less than 0.01) smaller, atypical lesions of significantly (P less than 0.01) shorter duration and devoid of or containing fewer T. pallidum organisms than lesions in the remaining immunized and control animals (Wicher et al., 1991).
References
Wicher et al., 1991: Wicher K, Schouls LM, Wicher V, Van Embden JD, Nakeeb SS. Immunization of guinea pigs with recombinant TmpB antigen induces protection against challenge infection with Treponema pallidum Nichols. Infection and immunity. 1991; 59(12); 4343-4348. [PubMed: 1937794].